Biotin — sole-added-active oral product,
does it really help with Lower HbA1c in adults with type 2 diabetes?
research showsWithin the documented search in adults with type 2 diabetes, no directly eligible between-group result was verified showing that sole-active oral biotin add-on lowers HbA1c compared with matched background care. A ? grade and null score do not mean no effect or no human studies worldwide.
ads claimFasting-glucose or chromium-mixture findings must not be presented as HbA1c benefit from biotin alone.
Four separate assessment dimensions
| Effect direction and size | No directly eligible between-group HbA1c result for sole-active oral biotin in adults with type 2 diabetes was verified |
|---|---|
| Evidence certainty | ? is scoped direct-evidence uncertainty, not no effect |
| Applicability | Adults with type 2 diabetes; oral biotin as the sole added active ingredient; matched-background placebo, no biotin supplement, or usual care |
| Safety | Caution |
B / S / null / null / null / null / null; score and strength count null
Useful facts when choosing a product
- Biotin can be evaluated as an add-on when the same standard diabetes care is maintained in both arms. Mixtures in which another active also changes, confirmed deficiency correction, type 1, gestational and drug-induced diabetes are not direct evidence for this claim. Unreported biotin status was not presumed normal.
- The eligible regimen, chemical form, formulation, dose, duration, HbA1c follow-up, denominators, between-group estimate, confidence interval, P value and clinical-importance threshold are unverified. Medication changes, rescue care, diet/exercise, red-cell lifespan, anemia, transfusion, hemoglobin variants, renal function and assay methods were not inferred beyond the verified scope.
Chamgap Semantic Classification Code
Permanent code issued
S.biotin.oral.adult-type-2-diabetes-hba1c.reduce.placebo-no-treatment-or-usual-careSubstances and nutrients > Biotin (vitamin B7), sole active ingredient > Oral > HbA1c in adults with type 2 diabetes > Reduction claim > Matched-background placebo, no biotin supplement, or usual care
Only the between-group HbA1c contrast is fixed; fasting/postprandial glucose, type 1 diabetes, and chromium-biotin combinations remain separate boundaries. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Biotin (vitamin B7), sole added active ingredient |
| Source or part used | Not verified: exact chemical form, origin and manufacturer of an eligible product. |
| Formulation or processing | Sole-active oral product is the question boundary; eligible formulation, excipients, batch and purity not verified. |
| Route | Oral; topical and injectable routes excluded. |
| Dose | Not verified: eligible dose, frequency, dietary and concurrent supplemental totals. |
| Duration | Not verified: eligible treatment duration and prespecified HbA1c follow-up. |
| Population | Adults with type 2 diabetes; confirmed deficiency correction, type 1, gestational, drug-induced diabetes, prediabetes and healthy populations separate. Unreported biotin status is not presumed normal. |
| Effect or condition | Lower HbA1c concentration. |
| Primary endpoint | Between-group HbA1c change difference at a prespecified follow-up, in percentage points; appropriately adjusted endpoint contrast separate. Not FPG, PPG, insulin, HOMA-IR or fructosamine. |
| Comparator | Matched-background placebo, no biotin supplement or usual care; actual eligible comparator not verified. Standard diabetes therapy is recorded separately. |
| Duplicate-detection key | biotin|sole-added-active-oral|adult-type2-diabetes|hba1c-between-arm-change-percentage-points|matched-background-placebo-no-supplement-usual-care|dose-time-unverified |
What the research actually shows
The Devi/Ranjani trial allocated 60 participants, 30 per arm, and used metformin 500 mg/day for 6 weeks in both arms. The biotin arm used 5 mg 2 times daily for 4 weeks followed by 2 weeks off biotin. This sole-added-active contrast was not excluded merely because of background medication. However, the verified weekly outcomes were fasting/postprandial glucose; no HbA1c result was verified.
Why this is classified as ?
Publication uses the original calculator’s direct-eligible-result gate: ? with a null score. HbA1c is an S surrogate for this question; the five later axes are unscored nulls. New direct results, full texts, registry information, corrections, retractions or numerical/classification errors trigger a revision history at the same assigned ID and URL.
Counterpoint. Some registry bodies, histories, protocols, SAPs and older full texts could not be fully obtained. GUTERRING has a candidate biotin-only arm, so it was not excluded merely because its title mentions a combination; a direct type 2 diabetes HbA1c result was not verified. Access failures were not counted as negative results or worldwide study absence.
Rejudgment record. Direct eligible result not verified — Original rubric/calculator stage zero and task-specific current-value policy; other analytes and mixtures excluded.
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
Stored derived and displayed grades match; this is not a current recalculation or validity check (?).
Review performed and remaining limitations
Eligible formulation, dose, duration, HbA1c follow-up, denominators, between-group effect, CI, P value, MCID and assay remain unverified
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Maebashi 1993 protocols | Small controlled supplement protocol; sequence/allocation not verified. | HbA1c analysis denominator unverified; other denominators in numeric_evidence.json. | Study-specific verified and unverified fields are in trial_families.json. | Fasting-glucose and serum-biotin outcomes are not an HbA1c group comparison. Long-term combination arm separate. | Fasting-glucose and serum-biotin outcomes are not an HbA1c group comparison. Long-term combination arm separate. | Excluded from direct efficacy grading |
| Báez-Saldaña 2004 + 2007 erratum | Randomized double-blind 28-day protocol after cross-sectional phase. | HbA1c analysis denominator unverified; other denominators in numeric_evidence.json. | Study-specific verified and unverified fields are in trial_families.json. | Baseline glycated hemoglobin is not a follow-up group contrast; metabolite table lacks a verified HbA1c change/end effect. | Baseline glycated hemoglobin is not a follow-up group contrast; metabolite table lacks a verified HbA1c change/end effect. | Excluded from direct efficacy grading |
| Revilla-Monsalve 2006 | Randomized double-blind placebo controlled, 28 days. | HbA1c analysis denominator unverified; other denominators in numeric_evidence.json. | Study-specific verified and unverified fields are in trial_families.json. | Lipid and fasting glucose/insulin results are not HbA1c. | Lipid and fasting glucose/insulin results are not HbA1c. | Excluded from direct efficacy grading |
| Chromium-biotin 90-day reports, conservative overlap cluster | Randomized double-blind placebo-controlled reports; possible shared cohort, not double-counted. | HbA1c analysis denominator unverified; other denominators in numeric_evidence.json. | Study-specific verified and unverified fields are in trial_families.json. | Different intervention: chromium plus biotin; common background diabetes therapy does not isolate either supplement. | Different intervention: chromium plus biotin; common background diabetes therapy does not isolate either supplement. | Excluded from direct efficacy grading |
| Singer/Geohas chromium-biotin pilot | Pilot randomized placebo-controlled report; registry linkage provisional. | HbA1c analysis denominator unverified; other denominators in numeric_evidence.json. | Study-specific verified and unverified fields are in trial_families.json. | Chromium-biotin combination; no sole-biotin HbA1c result verified. | Chromium-biotin combination; no sole-biotin HbA1c result verified. | Excluded from direct efficacy grading |
| Hemmati 2013 type1 study | Randomized placebo-controlled biotin add-on to insulin (primary abstract). | HbA1c analysis denominator unverified; other denominators in numeric_evidence.json. | Study-specific verified and unverified fields are in trial_families.json. | Different population: type1 diabetes, not adult type2. | Different population: type1 diabetes, not adult type2. | Excluded from direct efficacy grading |
| Devi/Ranjani 2016 metformin add-on | Single-center computer-randomized open-label controlled trial. | HbA1c analysis denominator unverified; other denominators in numeric_evidence.json. | Study-specific verified and unverified fields are in trial_families.json. | Sole biotin incremental intervention is allowed, but only fasting/postprandial glucose—not HbA1c—was verified. | Sole biotin incremental intervention is allowed, but only fasting/postprandial glucose—not HbA1c—was verified. | Excluded from direct efficacy grading |
| GUTERRING NCT05832190 | Official indexed pilot open-label randomized four-arm design. | HbA1c analysis denominator unverified; other denominators in numeric_evidence.json. | Study-specific verified and unverified fields are in trial_families.json. | Eligible type2 HbA1c results not verified; presence of a biotin-only arm means not excluded solely for combination wording. | Eligible type2 HbA1c results not verified; presence of a biotin-only arm means not excluded solely for combination wording. | Excluded from direct efficacy grading |
| Coggeshall 1985 older report | Not verified beyond bibliographic discovery. | HbA1c analysis denominator unverified; other denominators in numeric_evidence.json. | Study-specific verified and unverified fields are in trial_families.json. | Article found but full adult-type2 HbA1c contrast not verified. | Article found but full adult-type2 HbA1c contrast not verified. | Excluded from direct efficacy grading |
Receipt — 17 References
Evidence access cutoff: 2026-09-15. Each citation states its actual access level (full-text transcription, abstract, index, or other) and remaining limitations. Bibliographic checking does not certify the study results or treatment efficacy.
Technical integration by: Codex · Evidence date: 2026-09-15 · Corrections: none
Cite this verdict
[Chamgap] Does oral biotin alone lower HbA1c in adults with type 2 diabetes? — Evidence Grade ?. 17 cited sources checked. Source: https://chamgap.com/en/verdicts/blood-sugar/oral-biotin-alone-type-2-diabetes-hba1c/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.